Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel oral suspension adjunctive therapy in children with partial-onset or primary generalized tonic-clonic seizures
2014-002167-16Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2016
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of perampanel in epilepsy, Focal onset seizure and tonic-clonic seizure (GTCS) (2 cohorts), sponsored by Eisai Co., Ltd. Primary endpoint: Safety and tolerability. Started Dec 2016; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsyFocal onset seizuretonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2014-002167-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002167-16.